Bronnen:
Chandran V, Fleischmann R, Lespessailles E, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: three year results from a phase 3 study (SPIRIT-P1). EULAR 2018. Abstract THU0333.,Merola JF, Rich P, Dutz JP, et al. Ixekizumab improves nail and skin lesions through 52 weeks in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors. EULAR 2018. Abstract THU0313.,Kristensen L, Merola JF, Dutz J, et al. Ixekizumab improves nail and skin lesions in patients with active psoriatic arthritis and prior tnf inadequate response. Ann Rheum Dis 2017;76(Suppl 2):927.,Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis.2017;76:79-87.
Chandran V, Fleischmann R, Lespessailles E, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: three year results from a phase 3 study (SPIRIT-P1). EULAR 2018. Abstract THU0333.,Merola JF, Rich P, Dutz JP, et al. Ixekizumab improves nail and skin lesions through 52 weeks in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors. EULAR 2018. Abstract THU0313.,Kristensen L, Merola JF, Dutz J, et al. Ixekizumab improves nail and skin lesions in patients with active psoriatic arthritis and prior tnf inadequate response. Ann Rheum Dis 2017;76(Suppl 2):927.,Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis.2017;76:79-87.